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Abstract 
Background: Adrenocortical carcinoma (ACC) is an aggressive cancer with a 5 year survival rate of 20–30 %. Various 
factors have been implicated in the pathogenesis of ACC including dysregulation of the G2/M transition and aberrant 
activity of p53 and MDM2. Polo-like kinase 1 (PLK-1) negatively modulates p53 functioning, promotes MDM2 activ-
ity through its phosphorylation, and is involved in the G2/M transition. Gene expression profiling of 44 ACC samples 
showed that increased expression of PLK-1 in 29 % of ACC. Consequently, we examined PLK-1’s role in the modulation 
of the p53 signaling pathway in adrenocortical cancer.
Methods: We used siRNA knock down PLK-1 and pharmacological inhibition of PLK-1 and MDM2 ACC cell lines 
SW-13 and H295R. We examined viability, protein expression, p53 transactivation, and induction of apoptosis.
Results: Knocking down expression of PLK-1 with siRNA or inhibition of PLK-1 by a small molecule inhibitor, BI-2536, 
resulted in a loss of viability of up to 70 % in the ACC cell lines H295R and SW-13. In xenograft models, BI-2536 
demonstrated marked inhibition of growth of SW-13 with less inhibition of H295R. BI-2536 treatment resulted in 
a decrease in mutant p53 protein in SW-13 cells but had no effect on wild-type p53 protein levels in H295R cells. 
Additionally, inhibition of PLK-1 restored wild-type p53’s transactivation and apoptotic functions in H295R cells, while 
these functions of mutant p53 were restored only to a smaller extent. Furthermore, inhibition of MDM2 with nutlin-3 
reduced the viability of both the ACC cells and also reactivated wild-type p53′s apoptotic function. Inhibition of PLK-1 
sensitized the ACC cell lines to MDM2 inhibition and this dual inhibition resulted in an additive apoptotic response in 
H295R cells with wild-type p53.
Conclusions: These preclinical studies suggest that targeting p53 through PLK-1 is an attractive chemotherapy strat-
egy warranting further investigation in adrenocortical cancer.
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Background
Adrenocortical carcinoma (ACC) is a rare and often 
fatal cancer. Recent studies have shown that the out-
come for patients with ACC has remained essentially 
unchanged in the past 25  years, with the overall 5-year 
survival of patients undergoing surgical resection being 
approximately 40 % [1–3]. Patients who present clinically 
with large, locally invasive tumors resulting in involved 
surgical margins or those who present with metastatic 
disease fare considerably worse with 5 year survival rates 
of 10–20 % [1–3], largely due to the limited effectiveness 
of chemotherapy. The only realistic opportunity for cure 
is a complete surgical resection, but unfortunately meta-
static spread is already present in 40-70 % of patients at 
the time of diagnosis precluding cure [2–8]. Standard 
chemotherapy remains based on mitotane (Bristol-Myers 
Squibb Company, New York, New York) which was first 
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approved in 1960. Mitotane, also known as o,p’-DDD, is a 
derivative of the pesticide DDT and an adrenolytic [7, 9–
11]. The response rates to mitotane as a single agent is a 
relatively poor 23 %, but survival for those patients whose 
tumors do respond is improved from 14 to 50 months [7, 
9, 10, 12, 13]. For most patients, mitotane is poorly tol-
erated due to its severe toxic side effects, including the 
obliteration of the healthy contralateral adrenal gland. 
Although in the original phase II trial, etoposide, doxoru-
bicin, and cisplatin in combination with mitotane (EDP-
M), was reported to produce clinical response rates up 
to 49  % of patients in advanced ACC patients [14], the 
results were not substantiated in the phase III trial com-
paring this regimen to streptozocin and mitotane. In this 
trial, the response rate to EDP-M was 23.2  % and the 
median progression-free survival interval was 5  months 
[15]. Unfortunately, there is no approved second-line reg-
imen for those whose disease progress on these agents.
Increasing, new treatments for cancer are being devel-
oped based on the analysis of genomic aberrations iden-
tified in tumor samples from patients. An improved 
understanding of the molecular oncogenesis of adreno-
cortical cancer (ACC) may elucidate novel therapeu-
tic targets. The increased incidence of ACC in patients 
with Li-Fraumeni syndrome suggests the p53 pathway is 
involved in ACC progression [5, 6, 16]. In adults, how-
ever, mutation in p53 is seen in less than 25  % of cases 
suggesting that other elements of the p53 pathway may 
be perturbed [17–20]. Additionally, we and others have 
found that p53 is a major driver of differential gene 
expression when comparing ACC to normal adrenal 
glands or when comparing low and high-grade tumors 
[21, 22]. In the present analysis of gene expression pro-
files of ACC tumor samples, we found overexpression of 
polo-like kinase 1 (PLK-1), which is known to negatively 
regulate p53 activity, in 29 % of the tumors in our cohort 
and in 67 % of the tumors from the cohort published by 
Giordano, et  al. [23]. It has also been shown to interact 
with the human murine double minute 2 (MDM2) and 
control its activity [24]. Therefore, we sought to delineate 
the role of PLK-1 in the modulation of the p53 pathway 
in ACC. We examined the effect of pharmacologic inhibi-
tion of PLK-1 on p53 function.
Methods
Gene expression data
We used previously published data sets from Affymetrix 
U133 Plus 2 chips that included both normal adrenal 
and ACC samples annotated with survival data [22, 23] 
to identify the number of ACC samples over-expressing 
PLK1. The.CEL files from Affymetrix U133 Plus 2 chips 
were downloaded from GEO (GSE10297 and GSE19750). 
The data were filtered to include only normal adrenal 
samples without evidence of disease in the contralateral 
gland and ACC tumor sample from patients over 18 years 
of age. Using the Expression File Creator in GenePat-
tern [25], the data were normalized by gcRMA [26] with 
quantile normalization and background subtraction. 
Batch effects were minimized using COMBAT [27] with 
the non-parametric option, floored at 0.00001, and log2 
transformed. Normalized expression data was extracted 
for the PLK1 probe set (202240_at), and the relative fold 
change to the geometric mean of the corresponding nor-
mal samples for each study was computed. The total data 
set encompassed 7 normal adrenal glands and 75 ACC. 
Of the ACC, 43 had usable survival information.
We validated the survival trend observed with array-
based gene expression data using XENA [23] to pull out 
the mean normalized RSEM normalized count PLK1 
expression for the gene and survival data from the TCGA 
ACC cohort. We used the built in Kaplan–Meier plotting 
function to determine the expression level cut-offs for a 2 
group comparison for consistency, since there is no nor-
mal adrenal data in the TCGA data set.
To determine how SW-13 and H295R compared to 
tumors for PLK1 data, we mined GEO for PLK1 and beta-
actin expression in SW-13 and H295 (the parental line of 
H295R) as well as all available ACC expression data sets. 
We downloaded the data and extracted the expression 
values for the corresponding probes to PLK1 and beta-
actin, converted all data to log10, and plotted the results 
of PLK1 expression relative to beta-actin expression.
Eukaryotic cell culture
SW-13 and H295R cell lines were both purchased from 
ATCC (Manassas, VA). SW-13 cells were cultured in 
DMEM media with 10 % Fetal Bovine Serum (FBS), 1 % 
Penicillin–Streptomycin and 1  % l-Glutamine (all from 
Gibco, Grand Island, NY). H295R cells were cultured in 
DMEM/F12 media with 1 % Penicillin–Streptomycin, 1 % 
l-Glutamine (all from Gibco, Grand Island, NY), 2.5  % 
NuSerum and 1  % insulin-transferrin-selenium (ITS) 
(both from BD Biosciences, San Jose, CA). All cell cul-
tures were maintained in a 5 % CO2 atmosphere at 37 °C.
In vitro drug dose–response curves
Sensitivity to BI-2536 (Tocris, Minneapolis, MN, USA), 
mitotane (Tocris, Minneapolis, MN, USA) and nutlin-3 
(Tocris, Minneapolis, MN, USA) was tested in the follow-
ing manner. H295R cells were plated at a density of 1750 
cells/well in 40 µL of medium and SW-13 was plated at 
1250 cells/wells in 40 µL DMEM with 2 % FBS. For dose 
response curves with BI-2536 alone, twenty-four hours 
after plating, threefold serial dilutions of BI-2536 in 
10 μL of medium were added to the plates, with the final 
concentration at the highest dose being 100  µM. Cells 
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were then incubated for an additional 72, 96, or 120 h at 
37 °C in a humidified incubator. Viability was assessed by 
CellTiter Glo (Promega, Madison, WI, USA) and con-
verted to normalized percent viability after normalizing 
to cells alone and with drug carrier. Double compound 
studies were conducted as above except IC25 concentra-
tions (0.00684 µM for SW-13 and 0.0374 µM for H295R) 
of BI-2536 were kept constant and mitotane or nutlin-3 
was evaluated in serial dilution. In those cases, normal-
ized viability also included normalization to the median 
viability of BI-2536 alone.
Dose response curves and IC50 values for cell sur-
vival in the presence of the drugs were calculated using 
Prism5 software (GraphPad) using the log(inhibitor) vs. 
response—4 parameter function which fits the following 
equation: Y = Bottom + (Top–Bottom)/[1 + 10(X-LogIC50)] 
where X is the logarithm of concentration and Y is the 
percent cell survival. Y starts at the top and goes to bot-
tom with a sigmoid shape as X increases. All experiments 
were repeated at least three times with a minimum of five 
replicates per dose per experiment and values are repre-
sented as averages with standard error.
In vitro caspase 3/7 induction assays
Induction of apoptosis after treatment with BI-2536 and 
nutlin-3 alone or together in combination was deter-
mined using the Caspase 3/7 Glo assay (Promega, Mad-
ison, WI). H295R cells were plated at a density of 1750 
cells/well in 40  µl of medium and SW-13 was plated at 
1250 cells/wells in 40 µl DMEM with 2 % FBS. 24 h after 
plating, the cells were treated with 100  µM, 33.3  µM, 
11.1 µM, 3.703 µM and 1.234 µM of BI-2536 and nutlin-3 
in a 10 µl volume. Induction of apoptosis was determined 
by the cleavage of caspase 3/7 at 8, 16, 24 and 48 h after 
compound addition. 5  µM Doxorubicin (Tocris, Min-
neapolis, MN, USA) was used as a positive control for 
induction of apoptosis. Percent caspase 3/7 activity was 
normalized to cells and to DMSO control. Induction of 
apoptosis with double compounds was determined as 
above except IC25 concentrations (0.00684 µM for SW-13 
and 0.0374 µM for H295R) of BI-2536 were kept constant 
and nutlin-3 was evaluated in serial dilution. In those 
cases, percent caspase 3/7 activity was also normalization 
to the median caspase 3/7 activity of BI-2536 alone.
siRNA knockdown of PLK‑1
Using 6 well plates, 2 × 105 SW-13 and 3.5 × 105 H295R 
cells were plated in their respective media without anti-
biotics and allowed to attach overnight. The next day, for 
SW-13 Lipofectamine2000 reagent (Invitrogen, Carls-
bad, CA, USA) and for H295R TransIT-siQUEST reagent 
(Mirus Bio, Madison, WI, USA) was used to transfect in 
20  nM PLK-1 siRNA (Qiagen, Valencia, CA, USA), an 
all-stars negative siRNA (Qiagen, Valencia, CA, USA) as 
a negative control, or a universally lethal positive-control 
siRNA directed against ubiquitin B (UBBs1) [28] (Qiagen, 
Valencia, CA, USA) using the manufacturer’s recom-
mended protocols respectively. For transfection of SW-13 
cells, 5 µl of Lipofectamine 2000 and 20 nM PLK-1, neg-
ative-control, or UBBs1 siRNA were mixed together in 
equal volumes, in serum free media (SFM) and allowed to 
incubate at room temperature for 30 min. All the media 
from the SW-13 wells was aspirated off and 500 µl of the 
siRNA—Lipofectamine 2000 mix was added to each well 
along with 1.5 ml of media without antibiotics. For trans-
fection of H295R cells, 4 µl of TransIT-siQUEST reagent 
was diluted in SFM. 20  nM PLK-1, negative-control or 
UBBs1 siRNA were added to the diluted transfection 
reagent and allowed to incubate at room temperature for 
20 min. 250 µl of the siRNA—TransIT-siQUEST mix was 
added to each well containing 1.25 ml of media without 
antibiotics. PLK-1 protein knockdown was confirmed by 
immunoblot 72 h after transfection.
To determine cell viability after PLK-1 transfection, 
SW-13 cells were reverse transfected with siRNA to 
PLK-1 or control siRNA and assayed for viability after 
96 h. Briefly, 384 well plates were printed with 20 nM of 
Hs_PLK-1_7 siRNA, UBBs1, or negative control siRNAs 
that included a non-silencing scrambled siRNA and a 
siRNA directed against green fluorescent protein (GFP). 
A total of 20  µl of diluted Lipofectamine2000 solu-
tion was added to each well. After 30 min, 1200 cells for 
SW-13 in 20 µl of medium were added per well and then 
cultured at 37  °C. After 96  h, viability was assessed by 
CellTiter Glo following the manufacturer’s protocol. Rel-
ative luminescence values were normalized to cells and 
to cells with transfection agent to get normalized per-
cent viability. To determine viability of H295R cells after 
PLK-1 transfection, H295R were transfected with PLK-1, 
negative-control or UBBs1 siRNA and assayed for viabil-
ity after 72 h. Briefly, 20,000 H295R cells were plated in 
80  µl in 96 well plates and allowed to attach overnight. 
The next day 20  µl of TransIT-siQUEST reagent and 
20 nM PLK-1, negative-control or UBBs1 siRNA in SFM 
were added to each well containing 80 µl of media with-
out antibiotics. Cells were assayed for viability using 
CellTitre Glo 72 h after transfection as per the manufac-
turer’s protocol. Relative luminescence values were nor-
malized to cells alone and then cells with transfection 
agent alone to get normalized percent viability.
Total RNA extraction
6 × 105 SW-13 and 7.5 × 105 H295R cells were plated in 
10  cm2 dishes in 10  ml of media. Cells were allowed to 
adhere for 24 h and were then treated with their respec-
tive BI-2536 IC10, IC25 and IC50 doses including DMSO 
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controls. Total RNA was extracted 24  h later using the 
mirVana miRNA Isolation Kit (Ambion, Inc, Grand 
Island, NY, USA) as per the manufacturer’s protocol for 
total RNA extraction. This kit efficiently extracts RNAs 
larger than 10 nucleotides with specific protocols for 
either total RNA extraction or small RNA extraction. 
This allows us to use the kit for all experiments, reducing 
variability due to differences between kits.
RT‑qPCR validation of p53 and p21 mRNA levels
Total RNA was reverse transcribed utilizing both random 
hexamer and oligo-dT primers and the RT2 First Strand 
cDNA Synthesis Kit (SABiosciences, Valencia, CA, USA). 
The resulting cDNA was amplified on the iQ5 Real-
Time PCR Detection System (Bio-Rad Laboratories, Inc, 
Hercules, CA, USA) using primer sets for TP53 (p53), 
CDKN1A (p21) and ACTB (β-actin) and RT2 SYBR 
Green Master Mix (all from SABiosciences, Valencia, 
CA, USA) and run according to manufacturer’s instruc-
tions. Melting curve analysis was performed to evaluate 
primer set specificity. Fold difference with respect to the 
vehicle control, DMSO, and relative to β-actin, which was 
used as the reference gene, was calculated using the Pfaffl 
method taking into account reaction efficiencies [29].
Western blot analysis
6 × 105 SW-13 and 7.5 × 105 H295R cells were plated in 
10  cm2 dishes in 10  ml of media. Cells were allowed to 
attach for 24 h after which they were treated with IC10, 
IC25, IC50 concentrations of BI-2536 (Table 1) and DMSO 
vehicle control for 24 h. Cells were lysed with RIPA buffer 
with protease and phosphatase inhibitors, and the result-
ing protein lysate quantitated by BCA (Pierce, Thermo 
Scientific, Pittsburgh, PA, USA). Thirty micrograms of 
protein were loaded onto 4–12  % Bis–Tris pre-cast gels 
(Invitrogen, Carlsbad, CA, USA) and allowed to sepa-
rate at 150 V for 1 h. The gels were then transferred onto 
PVDF membranes for 7  min using the iBLOT west-
ern transfer system (Invitrogen, Carlsbad, CA, USA) at 
room temperature. Following the transfer of proteins, the 
membranes were blocked in 5 % blocking solution made 
from, non-fat dry milk dissolved in 1x TBST (50  mM 
Tris.HCl, pH 7.4, 150 mM NaCl + 0.1 % Tween 20) for 
1 h. Primary PLK-1 antibody (Cell Signaling, Technology, 
Danvers, MA, USA) at a dilution of 1:500 was added to 
membranes in 5 % BSA (1× TBST + 5 % BSA) overnight 
at 4  °C. Primary antibodies to MDM2 (AbCam, Cam-
bridge, MA, USA) and p53 (AbCam, Cambridge, MA) 
at a dilution of 1:500 were added to the membranes in 
1 % blocking solution overnight at 4 °C. The next day the 
membranes were washed with 1× TBST twice for 10 min 
and appropriate HRP labeled secondary anti-rabbit (Cell 
Signaling Technology, Danvers, MA, USA) for PLK-1 and 
anti-mouse (Cell Signaling Technology, Danvers, MA, 
USA) for MDM2 and p53 antibodies were added to the 
blots at a dilution of 1:1000 for 2 h at room temperature. 
The blots were then washed in 1x TBST four times for 
10 min. The membranes were developed using the Super-
Signal West Femto Chemiluminescent Substrate (Pierce, 
Thermo Scientific, Pittsburgh, PA, USA) and were visual-
ized and quantitated with the Bio Spectrum 500 Imaging 
System (UVP, Cambridge, UK).
The blots were processed as described above for the 
detection of β-Actin (AbCam, Cambridge, MA, USA) in 
5 % blocking solution which was used as an internal load-
ing control. The β-Actin antibody was used at a dilution 
of 1:1000 along with the anti-rabbit secondary antibody 
also at a dilution of 1:1000. The actin membranes were 
also detected using the SuperSignal West Femto Chemi-
luminescent Substrate (Pierce, Thermo Scientific, Pitts-
burgh, PA, USA) and were visualized and quantitated 
with the Bio Spectrum 500 Imaging System (UVP, Cam-
bridge, UK) and relative amounts of PLK-1, MDM2 and 
p53 protein are reported relative to β-Actin. All experi-
ments were done three individual times and are repre-
sented as averages with standard error.
To determine PLK-1 protein expression after siRNA 
knockdown, blots for PLK-1 and β-Actin were processed 
as described above. Relative amounts of the PLK-1 pro-
tein after siRNA knockdown are reported relative to 
β-Actin. All experiments were done three individual 
times and are represented as means with standard error.
In vivo sensitivity assays
For in  vivo testing of drug efficacy, xenograft models 
in female ncr nude mice were used. H295R and SW-13 
were utilized in the creation of mouse xenograft tumors. 
All procedures were carried out under the institutional 
guidelines of TGen Drug Development’s Institutional 
Animal Care and Use Committee (Protocol #06001, 
initially approved January 2006). To create xenografts, 
5.0 × 106 cells were injected subcutaneously in a solution 
of 50 % media/50 % Matrigel™ into the right flank of the 
animal. Cohorts were assigned by random-equilibration 
into groups of 10 for SW-13 or groups of 9 for H295R. 
On Day 1, mitotane was diluted with a corn oil solution 
immediately prior to dosage administration to working 
concentration of 30 mg/ml in order to deliver 300 mg/kg 
Table 1 BI-2536 inhibitory concentrations
Cell line BI‑2536 (µM)
IC10 IC25 IC50
H295R 0.00565 0.00684 0.0095
SW-13 0.0222 0.0374 0.0628
Page 5 of 14Bussey et al. Clin Trans Med  (2016) 5:1 
doses at a 0.2 ml fixed dose volume. Mitotane was given 
daily by oral gavage administration for 20 days. BI-2536 
(30 mg/kg) was administered twice weekly by IP injection 
[30]. When the mean tumor weight of the control group 
reached 1500 mg, the study was terminated. Tumors were 
measured using Vernier calipers and tumor weight calcu-
lated using the formula: Tumor weight (mg) = (a × b2/2) 
where ‘b’ is the smallest diameter and ‘a’ is the largest 
diameter. Body weights were recorded when the mice 
were pair-matched. In addition, body weights were taken 
twice weekly thereafter in conjunction with tumor meas-
urements. Mean tumor growth inhibition (TGI) was cal-
culated utilizing the following formula:
 Tumors that regressed from the Day 1 starting size were 
removed from the calculations. All statistical analyses 
in the xenograft study were performed with GraphPad 
Prism® v4 software. Differences in final tumor weights 
were confirmed using the Analysis of Variance (ANOVA) 
with Tukey’s Multiple Comparison Test.
Statistical analysis
All statistical analyses were done with the Prism6 soft-
ware (GraphPad) and included Analysis of Variance 
(ANOVA) with Tukey’s Multiple Comparison Test, Two-
Way ANOVA with Dunnett’s multiple comparison test, 
and Survival using the log-rank method as implemented 
by the software. Cox Proportional Hazards were com-
puted in R using the Survival package with stratification 
of samples by residual tumor status. P-values below 0.05 
were considered strong a strong indication of non-ran-
dom results, but where we report a trend, a p value is also 
reported even if it was above 0.05 to allow the reader to 
judge the non-random nature of the trend.
Evaluation of p53 and MDM2 genotypes
Studies of p53 mutations, p53 codon 72 polymorphism, 
and MDM2 SNP309 polymorphism are detailed in the 
Additional file 1, as the results of the studies were largely 
negative.
Results
Inhibition of Polo‑like kinase 1 (PLK‑1) reduced the viability 
of ACC cell lines
Examination of our gene expression data [22] combined 
with that of Giordano, et al. [23]. revealed that PLK1 was 
over-expressed in 37 % of tumors with a mean log2 fold-
change relative to normal adrenal of 7.88 (range −0.0589 
to 30.74, Additional file 1: Table  S3). There was no cor-
relation between the expression levels of PLK1, MDM2, 
TGI =
[
1−
χ¯Treated (Final) − χ¯Treated (Day1)
χ¯Control (Final) − χ¯Control (Day1)
× 100%
]
and TP53. Since increased PLK-1 expression has been 
correlated to poor prognosis and aggressiveness of can-
cers, we evaluated whether a similar association exists 
in ACC. We found that patients with tumors that had 2 
fold or greater over-expression had a median survival of 
1.585 years compared to a median survival 4.753 years for 
patients with tumors having near normal PLK1 expres-
sion levels (Fig.  1a), yielding a log-rank hazard-ratio 
(HR) of 2.188 (95  % confidence interval 1.289–6.207). 
We obtained similar results using the gene average PLK1 
expression data from TCGA for ACC (Fig.  1b), with a 
log-rank HR of 7.773 (95  % confidence interval 7.441–
48.28). We used the TCGA data to examine clinical cor-
relates. The only correlation observed was the residual 
tumor status. Tumors classified as R0 had less expres-
sion of PLK1 compared to tumors that were classified 
as R1, R2 or RX (Fig. 1c). The Cox proportional HR for 
PLK1 expression taking into account the residual tumor 
status was 1.626 (95  % confidence interval 1.124–2.351, 
p = 0.00979).
Next we wanted to determine the effect of downregu-
lating PLK-1 on the ACC cell lines. We found that knock-
ing down expression of PLK-1 using siRNA not only 
reduced the amount of PLK-1 protein (Fig.  2a, b), but 
also decreased the viability of both H295R and SW-13 
to levels close to that of the positive control, UBB1, after 
siRNA knockdown (Fig. 2c), demonstrating that the ACC 
cell lines were very sensitive to the loss of PLK-1.
Similarly, exposure to the PLK-1 inhibitor BI-2536 
showed that both H295R and SW-13 cell lines were 
also extremely sensitive to PLK-1 inhibition (Fig.  2d, e). 
H295R had an IC50 value of 0.063 µM while SW-13 was 
~tenfold more sensitive compared to H295R with an 
IC50 value of 0.0095  µM 120 and 96  h following addi-
tion of drug respectively (Fig. 2d, e; Table 2). These val-
ues are well below the concentrations achieved clinically 
(31.2–55.2  µM) following a single intravenous injection 
of 50–70 mg of BI-2536 [31], but well with in the range of 
IC50 responses seen in a variety of cancer cell lines (Addi-
tional file 1: Figure S2).
As mitotane is the current standard of care for patients 
with advanced ACC [2, 4, 11, 13], we wanted to deter-
mine whether inhibition of PLK-1 could sensitize ACC 
cell lines to mitotane. Combined treatment with BI-2536 
and mitotane did not increase the sensitivity of SW-13 or 
H295R ACC cell lines to mitotane (Fig. 3a, b).
We also studied the efficacy of BI-2536 in a murine 
xenograft model of ACC. Marked inhibition of tumor 
growth in response to BI-2536 relative to either vehicle 
control or mitotane-treated tumors was observed for 
SW-13 xenografts while the inhibition in H295R (Fig. 3c, 
d) was less dramatic, recapitulating the in vitro cell viabil-
ity data (Fig. 3a, b; Table 3). The lack of response of the 
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xenografts to mitotane is not surprising given that clini-
cally less than 25 % of patients respond to the drug alone 
or in combination [11, 12, 15]. Thus, PLK-1 loss either by 
silencing with siRNA or through pharmacological inhibi-
tion with BI-1536 dramatically impacts ACC cell viability 
both in vitro and in vivo.
Inhibition of PLK‑1 reduced levels of mutant p53 protein 
but not wild type p53
PLK-1 is a negative modulator of p53 activity but has 
not been shown to affect its levels [32]. Therefore, we 
would predict that inhibition of PLK-1 would not affect 
p53 protein levels in ACC. Treatment with BI-2536 did 
not affect the levels of p53 transcript in either of the two 
cell lines (Fig. 4a). However, using an antibody that rec-
ognizes both mutant and wild-type p53 with its multiple 
isoforms, we saw a dose-dependent decrease of mutant 
p53 protein levels in SW-13 cells but not in the wild-type 
p53 protein levels in H295R cells (blots—Fig. 4b; quanti-
fication of blots Fig. 4c, d).
Inhibition of PLK‑1 restores functioning of wild type p53
Since PLK-1 is a negative modulator of p53, inhibi-
tion of PLK-1 would relieve the negative regulation 
on wild-type p53 and potentially restore its transac-
tivation and apoptotic functions. In the context of 
the predicted non-functional transactivation of the 
mutant p53 in SW-13, we would expect little impact 
on transactivation and unknown impact on apoptosis, 
particularly in light of the loss of mutant p53 protein 
upon BI-2536 exposure. We assessed p53’s transac-
tivation and apoptotic functions after treatment with 
BI-2536. Inhibition of PLK-1 with BI-2536 resulted in 
a slight increase in the transcription of CDKN1A (gene 
that encodes the p21 protein) in H292R cells with wild 
type p53 (Fig.  5a). On the other hand, a decrease in 
mutant p53 protein in SW-13 cells after exposure to 
BI-2536 also reduced the amount of CDNK1A message 
(Fig. 5b). Furthermore, we tested whether inhibition of 
PLK-1 with BI-2536 could also restore p53’s apoptotic 
function. Treatment with BI-2536 resulted in a robust 
Fig. 1 High PLK1 mRNA expression is associated with worse prognosis in ACC tumors. a In data from Affymetrix U133 plus 2 arrays, tumors that 
exhibit a log2 fold-change of 2 or greater relative to normal have a worse overall survival compared to tumors that express less PLK1 mRNA. b The 
relationship between PLK1 mRNA expression and shorter survival times was validated by RNA sequencing data from TCGA. c In the TCGA data set, 
the only clinical parameter associated with PLK1 expression is residual tumor status
Page 7 of 14Bussey et al. Clin Trans Med  (2016) 5:1 
induction of apoptosis after treatment with BI-2536 in 
H295R cells (Fig.  5c) and to a lesser extent in SW-13 
cells with mutant p53 (Fig.  5d). However, maximum 
induction of apoptosis in SW-13 cells was observed 
at 48  h, while only high concentrations of BI-2536 
resulted in an increase in apoptosis at early time points 
(Fig. 5c, d).
Fig. 2 Inhibition of Polo-like kinase 1 (PLK-1) reduced the viability of ACC cell lines: Given that PLK-1 is a negative regulator of p53, inhibition of 
PLK-1 should reduce viability of the ACC cell lines. a ACC cell lines, H295R and SW-13 were treated with PLK-1 siRNA and amount of PLK-1 protein 
was determined after 72 h of siRNA treatment. b Quantitation of PLK-1 protein western after siRNA knockdown expressed relative to β-actin. c 
Knocking down expression of the PLK-1 protein reduced viability of the H295R & SW-13 cell lines as compared to the controls. d, e Similarly, treating 
the cells with BI-2536, an inhibitor of PLK-1, reduced the viability of both the H295R and SW-13 ACC cell lines. Assays were normalized first to cells 
alone and then to a vehicle control. This resulted in viability measures of greater than 100 %. All experiments were done at least three individual 
times and data are represented as means with standard error. TF Transfection agent and NT Non-targeting siRNA. Uncropped images of full blots 
with molecular weight markers can be found in the Additional file 1: Figure S1
Table 2 IC50 values of  BI-2536 and  nutlin-3 alone and  in 
combination
IC50 values H295R SW13
BI-2536 0.0628 µM 0.0094 µM
Nutlin-3 12.75 µM 19.78 µM
Nutlin-3 + BI-2536 2.838 µM 6.502 µM
Combination Index 0.22 0.33
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Synergy of PLK‑1 inhibition by BI‑2536 with MDM2 
inhibition by nutlin‑3
While both PLK-1 and MDM2 regulate p53 activity inde-
pendently, they also cooperate to modify p53 function. 
PLK-1 phosphorylates MDM2 at serine 260, stimulat-
ing the activity of MDM2 and increasing the turnover 
of p53 [24]. We therefore also determined the effect of 
BI-2536 treatment on MDM2 protein levels and found 
that inhibition of PLK-1 did not affect the levels of the 
MDM2 protein (Fig. 6a, b). We also determined whether 
inhibiting MDM2 with nutlin-3, an inhibitor of MDM2 
would reduce viability of ACC cells, presumably as a 
result of the restoration of p53 functions. Treating both 
H295R and SW-13 cells with nutlin-3 decreased their cell 
viability (Fig. 6c) and restored wild type p53’s apoptotic 
response in H295R cells (Fig.  6d, e). Given that PLK-1 
directly modulates p53 functions as well as indirectly by 
modulating MDM2 functions, we wanted to determine 
inhibiting PLK-1 would sensitize cells to the effects of 
nutlin-3, an inhibitor of MDM2. We observed a decrease 
in the IC50 values of nutlin-3 when it was combined with 
the IC25 concentration of BI-2536 after controlling for 
the effect of BI-2536 itself in both the cell lines (Fig. 7a, 
Fig. 3 Effect of BI-2536 and mitotane on SW-13 and H295R cell lines and their tumor xenografts: Mitotane and BI-2536 did not lead to increased 
cell death in either SW-13 (a) or H295R (b) as compared to mitotane alone. The above experiments were done 3 individual times and data are pre-
sented as means with standard error. BI-2536 showed inhibited tumor growth to a greater extent in xenografts of SW-13 (p = 0.0001 versus vehicle, 
p = 0.0002 versus mitotane, c compared to the H295R xenograft model (p = 0.445 versus control, p = 0.0295 versus mitotane, (d). The difference in 
response may be due to the difference in p53 status of the cell lines. SW-13 is heterozygous for a mutation in p53 while H295R is wild-type for p53
Table 3 IC50 values mitotane alone and  in combination 
with BI-2536
IC50 values H295R SW13
Mitotane 13.45 µM 7.36 µM
Mitotane + BI-2536 10.49 µM 13.34 µM
Combination Index 0.78 1.81
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b; Table  2). This effect was independent of p53 muta-
tion status, as both ACC cell lines responded in a similar 
fashion. 
Inhibition of PLK-1 and MDM2 should result in the 
reactivation of p53’s apoptotic function, due to dual relief 
of p53 inhibition [33]. However, combined inhibition of 
PLK-1 and MDM2 did not increase apoptotic response 
of SW-13 over that seen with BI-2536 alone, whereas an 
additive apoptotic response was observed in H295R cells 
with wild-type p53, which is responsive to MDM2 inhibi-
tion (Fig. 7c, d).
Discussion
Adrenocortical cancer remains a difficult malignancy to 
treat. New therapeutic regimens have not been forth-
coming in part due to the relative rarity of the disease. 
Recently, the two major phase III studies, the FIRM-ACT 
trial and the OSI-906 study have been completed. The 
FIRM-ACT study was designed to establish a first-line 
chemotherapy standard which at this point is generally 
accepted by the ACC community as the combination of 
EDP-M [15]. The OSI-906 study was done to investi-
gate the efficacy of a small molecule IGF1R inhibitor in 
patients whose tumors have progressed on multiple drug 
chemotherapy. Alas, the results did not show improve-
ment in progressive free survival in the treatment arm, 
although a small number of patients did appear to derive 
benefit [34]. Clearly, a need still exists for further study 
and better treatments. The advent of rapid and high 
throughput methods for genomic analysis offers the 
potential ability to accelerate the process of identifying 
therapeutic leads. Candidate agents must still undergo 
Fig. 4 Inhibition of PLK-1 reduces expression of mutant p53 protein in SW13 cells: Since PLK-1 has been shown to physically interact with p53 to 
control its functions; the levels of the p53 protein should not be affected after inhibition of PLK-1. a Inhibition of PLK-1 with BI-2536 did not reduce 
transcript levels of either wild type or mutant p53 as determined by qRT-PCR. b However, BI-2536 treatment resulted in a decrease in the amount of 
mutant p53 protein in the SW-13 cells, but not of the wild type p53 protein in the H295R cells. c, d Quantitation of PLK-1 and p53 protein westerns 
after BI-2536 treatment expressed relative to β-actin. This confirms that p53 protein expression decreased in SW-13 and remains constant in H295R. 
All experiments were done at least 3 individual times and data are represented as means with standard error. The same western blots were stripped 
and re-probed for multiple proteins. Thus, the blots were cropped for ease of presentation. Uncropped blots with molecular weight standards can 
be found in the Additional file 1: Figure S2
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traditional preclinical evaluation and those agents that 
are promising should then be entered into clinical trials 
to evaluate their efficacy in ACC.
Our studies on p53 in adrenocortical cancer are, in 
general, consistent with the findings of others. We found 
that p53 mutations in adult sporadic ACC are relatively 
uncommon. Others have previously reported mutation 
rates of 10–27 % [18–20, 35–37]. The increased incidence 
of ACC in children who have Li-Fraumeni syndrome, 
characterized by an inactivating mutation of p53 [38], 
however, suggests that one should examine the p53 path-
way further in adults with ACC. Analysis of our expres-
sion array ACC data confirms that there is perturbation 
of the p53 pathway in many ACC cases, leading to the 
conclusion that there are mechanisms other than p53 
mutation involved [22].
Targeting of other modifiers of p53 activity is a viable 
approach. One candidate therapeutic compound target-
ing polo-like kinase 1 (PLK-1) is advanced in this study. 
Polo-like kinases are a group of highly conserved serine-
threonine kinases that regulate cell cycle checkpoints 
and cell division [39, 40]. PLK-1 is the most extensively 
studied, and it controls cell passage through M phase of 
the mitotic cycle [41]. PLK-1 mRNA is over-expressed in 
most human cancers including those of the breast, lung, 
stomach, colon and rectum, ovary, pancreas and prostate 
Fig. 5 Inhibition of PLK-1 restores p53 functioning: Since PLK-1 is a negative regulator of p53, inhibition of PLK-1 should restore p53 transactivation 
and apoptotic functions. a Treatment of H295R and SW-13 cells with BI-2536 resulted in the restoration of wild type p53’s transactivation functions 
as seen by the increased transcription of its downstream gene, CDKN1A (p21) determined by qRT-PCR. b However, BI-2536 treatment of the SW-13 
did not increase the transcription of CDKN1A, as it is mutant for p53 and the mutation is predicted to decrease p53 transactivation functions. c 
Furthermore, inhibition of PLK-1 restored wild type p53’s apoptotic response in H295R cells as determined by the Caspase 3/7 Glo assay. d The 
apoptotic response was slightly delayed in the SW-13 cells with mutant p53 with maximum response observed at 48 h. Doxorubicin was used as a 
positive control for apoptosis. All experiments were done at least 3 individual times, and data are represented as means with standard error
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[42]. Over-expression of PLK-1 in cancers is thought to 
portend an adverse prognosis [43, 44]. Our analysis of 
PLK1 expression relative to survival in our expression 
data [22] combined with that of Giordano et  al. [23] 
confirms this relationship in ACC. In vitro and in  vivo 
experiments have suggested PLK-1 plays a role in car-
cinogenesis [40, 45]. Inhibition of PLK-1 in  vitro leads 
to cell cycle arrest at G2/M and apoptosis in human 
cancer cell lines [39, 41]. Several PLK-1 inhibitors are 
under clinical development including BI-2536, which was 
investigated in phase II trials [30, 46] with mixed results. 
Another PLK-1 inhibitor, BI 6727 or volasertib in com-
bination with low-dose cytarabine is being studied in a 
phase III trial in patients with acute myeloid leukemia, 
after encouraging results in a phase II trial [47]. Our 
study offers evidence that BI-2536 may act to decrease 
levels of mutant p53 while not affecting wild type p53. 
It has been previously reported that BI-2536 has activity 
at nanomolar levels (IC50 range 0.002–0.025 µM) in cells 
lines that have either wild type or mutant p53 [30, 33]. 
It may be that patients with tumors harboring mutant 
p53 will respond to inhibition of PLK-1 by BI-2536 better 
than patients whose tumors harbor a wild-type p53. The 
results from our xenograft model are supportive of this. 
One attractive hypothesis that warrants investigation 
is that if one could inhibit mutant p53 and allow cancer 
Fig. 6 Inhibition of MDM2 by nutlin-3 restored wild type p53’s apoptotic response: Since PLK-1 also indirectly controls p53’s activity via MDM2, we 
determined the effect of PLK-1 inhibition on MDM2 functioning. a Inhibition of PLK-1 with BI-2536 did not change the levels of the MDM2 protein. 
b Quantitation of the MDM2 protein western after BI-2536 treatment expressed relative to β-actin. c Treating the cells with nutlin-3, an inhibitor of 
MDM2, reduced the viability of both the H295R and SW-13 ACC cell lines. d Furthermore, inhibition of MDM2 restored wild type p53’s apoptotic 
response in H295R cells as determined by the Caspase 3/7 glo assay. e However, a very small increase in apoptosis was observed in the SW-13 cells 
with mutant p53. Doxorubicin was used as a positive control for apoptosis. All experiments were done at least three individual times and data are 
represented as means with standard error. Uncropped blots that include molecular weight standards can be found in the Additional file 1: Figure S3
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cells to undergo apoptosis, one could enhance tumor 
response to treatment with other chemotherapeutic 
agents. In this way, a PLK-1 antagonist such as BI-2536 
could be used as part of a combination chemotherapeutic 
strategy to treat ACC.
The mechanism by which BI-2536 affects mutant 
p53 levels is unclear and should be studied further. 
Several explanations are possible. PLK-1 may act to 
stabilize mutant p53 and protect it from degrada-
tion or inactivation. Inhibition of PLK-1 may act at 
the transcription or translation level. Alternatively, 
BI-2536 may have a direct effect on p53 independent 
of its effect on PLK-1. Lastly, we cannot assess based 
on the current experiments whether the effects seen 
are particular to ACC or whether other tumor types 
would behave similarly.
We also considered MDM2, a major negative regula-
tor of p53, which was over-expressed at the RNA level in 
our samples. A single nucleotide polymorphism (SNP) 
at position 309 with a conversion of T to G generates a 
strong SP1 binding site and increases MDM2 expression 
[48, 49]. We did not observe a change in allele frequency 
from the expected population frequency in our ACC 
population, nor did we observe a significant increase 
MDM2 expression in tumors with a G allele compared to 
tumors homozygous for the T allele. Furthermore, ACC 
cell lines were relatively insensitive to pharmacological 
inhibition of MDM2. MDM2, therefore, seems unlikely to 
be the sole p53 regulator responsible for the disruption of 
p53 function in ACC. MDM2 remains of interest because 
agents targeting it, such as nutlins and in particular nut-
lin-3, are being investigated as anti-cancer drugs. These 
Fig. 7 Synergy of PLK-1 inhibition by BI-2536 with MDM2 inhibition by nutlin-3: Since PLK-1 plays a role in controlling p53 directly and via MDM2, 
we wanted to determine whether inhibition of PLK-1 would show synergy with MDM2 inhibition. a, b Indeed treatment of H295R (a) and SW-13 (b) 
cells with nutlin-3 and BI-2536 sensitized both the cell lines to nutlin-3. We also anticipated that dual inhibition of PLK-1 and MDM2 would result in 
a synergistic apoptotic response via p53. c, d Dual inhibition of PLK-1 and MDM2 resulted in an additive response in the H295R cells (c), with wild-
type p53, whereas no additive apoptotic response was seen in the SW-13 cells (d) with mutant p53. Doxorubicin was used as a positive control for 
apoptosis. All experiments were done at least three individual times and data are represented as means with standard error
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agents inhibit the interaction of MDM2 and p53 thereby 
stabilizing p53 leading to cellular senescence [33]. As 
such nutlin-3 may work best in tumors with a normal or 
wild-type p53 gene, therefore making it potentially use-
ful in the adult ACC patient population as approximately 
75 % of tumors harbor wild-type p53.
We conclude from these preclinical studies that tar-
geting p53 through PLK-1 is an attractive chemotherapy 
strategy warranting further investigation in adrenocorti-
cal cancer.
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